The Pharmaceutical Journal
Vol 278 No 7458 p759
30 June 2007

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Sorafenib rejected in Wales

Use of sorafenib (Nexavar; Bayer) in NHS Wales has been rejected by the All Wales Medicines Strategy Group.

The group made its decision on the basis of a lack of evidence for the drug’s cost-effectiveness, it says. The recommendation has been endorsed by Edwina Hart, the Welsh Assembly Government’s Minister for Health and Social Services. The Department of Health has not yet referred the drug to the National Institute for Health and Clinical Excellence, which covers England and Wales, and the AWMSG’s guidance is mandatory unless superseded by NICE guidance. The Scottish Medicines Consortium rejected the use of sorafenib in NHS Scotland last year.